A5010529757- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- COVID-19 epidemiological studies
- Geriatric Care and Nursing Homes
- Long-Term Effects of COVID-19
- Tuberculosis Research and Epidemiology
- Health disparities and outcomes
- Vaccine Coverage and Hesitancy
- Frailty in Older Adults
- COVID-19 and Mental Health
- Pneumocystis jirovecii pneumonia detection and treatment
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Pneumonia and Respiratory Infections
- SARS-CoV-2 detection and testing
- Legal Education and Practice Innovations
- COVID-19 Pandemic Impacts
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- Fungal Infections and Studies
- Nosocomial Infections in ICU
- Nail Diseases and Treatments
- Diagnosis and treatment of tuberculosis
- Autoimmune and Inflammatory Disorders Research
- Employment and Welfare Studies
University College London
2015-2025
Issues Research
2024
Royal Free London NHS Foundation Trust
2023
University College London Hospitals NHS Foundation Trust
2023
Foundation University Medical College
2021
Quaid-i-Azam University
2021
University College of Islamabad
2021
Health Data Research UK
2021
Barts Health NHS Trust
2019-2020
Institute of Informatics of the Slovak Academy of Sciences
2020
BackgroundThe effectiveness of SARS-CoV-2 vaccines in older adults living long-term care facilities is uncertain. We investigated the protective effect first dose Oxford-AstraZeneca non-replicating viral-vectored vaccine (ChAdOx1 nCoV-19; AZD1222) and Pfizer-BioNTech mRNA-based (BNT162b2) residents terms PCR-confirmed infection over time since vaccination.MethodsThe VIVALDI study a prospective cohort that commenced recruitment on June 11, 2020, to investigate transmission, outcomes, immunity...
BackgroundLong-term care facilities (LTCFs) have reported high SARS-CoV-2 infection rates and related mortality, but the proportion of infected people among those who survived, duration antibody response to natural infection, is unknown. We determined prevalence stability nucleocapsid antibodies (the standard assay for detection previous infection) in staff residents LTCFs England.MethodsThis was a prospective cohort study 65 years or older younger 201 England between March 1, 2020, May 7,...
SummaryBackgroundSARS-CoV-2 infection represents a major challenge for long-term care facilities (LTCFs) and many residents staff are seropositive following persistent outbreaks. We aimed to investigate the association between SARS-CoV-2 antibody status at baseline subsequent in this population.MethodsWe did prospective cohort study of (aged <65 years) >65 100 LTCFs England Oct 1, 2020, Feb 2021. Blood samples were collected June November, baseline, 2 4 months thereafter tested IgG...
The SARS-CoV-2 omicron variant (B.1.1.529) is highly transmissible, but disease severity appears to be reduced compared with previous variants such as alpha and delta. We investigated the risk of severe outcomes following infection in residents long-term care facilities.We did a prospective cohort study facilities England who were tested regularly for between Sept 1, 2021, Feb 2022, participants VIVALDI study. Residents eligible inclusion if they had positive PCR or lateral flow device test...
Residents and staff in long-term care facilities have been prioritised for vaccination against SARS-CoV-2, but data on potential waning of vaccine effectiveness the effect booster doses this vulnerable population are scarce. We aimed to evaluate one, two, three infection severe clinical outcomes residents England over first year following roll-out.
Abstract Third-dose coronavirus disease 2019 vaccines are being deployed widely but their efficacy has not been assessed adequately in vulnerable older people who exhibit suboptimal responses after primary vaccination series. This observational study, which was carried out by the VIVALDI study based England, looked at spike-specific immune 341 staff and residents long-term care facilities received an mRNA vaccine following dual series with BNT162b2 or ChAdOx1. strongly increased antibody...
Abstract Background The effectiveness of SARS-CoV-2 vaccines in frail older adults living Long-Term Care Facilities (LTCFs) is uncertain. We estimated protective effects the first dose ChAdOx1 and BNT162b2 against infection this population. Methods Cohort study comparing vaccinated unvaccinated LTCF residents England, undergoing routine asymptomatic testing (8 December 2020 - 15 March 2021). relative hazard PCR-positive using Cox proportional hazards regression, adjusting for age, sex, prior...
We have previously demonstrated that older residents of long-term care facilities (LTCF) in the UK show levels anti-spike antibodies are comparable to general population following primary series and booster vaccination for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, data on humoral response other SARS-CoV-2 proteins associated with natural infection scarce this vulnerable population.
<ns4:p>Global infection and mortality rates from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are disproportionately high in certain populations, including the elderly. Care home residents frequently exposed to due contact with staff other residents, highly susceptible their age co-morbidity. In England, official statistics suggest that at least 25% of all deaths care since start pandemic linked disease 2019 (COVID-19), but limited testing for SARS-CoV-2 early means estimates...
<ns4:p>Global infection and mortality rates from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are disproportionately high in certain populations, including amongst older people. Care home residents frequently exposed to due contact with staff other residents, highly susceptible their age co-morbidity. In England, official statistics suggest that at least 25% of all deaths care since the start pandemic linked coronavirus disease 2019 (COVID-19), but limited testing for...
Background: The effectiveness of SARS-CoV-2 vaccines in frail older adults living Long-Term Care Facilities (LTCFs) is uncertain. We estimated protective effects the first dose ChAdOx1 and BNT162b2 against infection this population. Methods: Cohort study comparing vaccinated unvaccinated LTCF residents England, undergoing routine asymptomatic testing (8 December 2020 - 15 March 2021). relative hazard PCR-positive using Cox proportional hazards regression, adjusting for age, sex, prior...
Background Vulnerable individuals with tuberculosis (TB) struggle to access and stay on treatment. While patient-related social barriers TB treatment adherence are well documented, less is known about how the organisation delivery of care influences behaviour. Aim To examine influence service culture patients' experience starting staying in Riga, Latvia. Methods An intervention package support amongst vulnerable patients Latvia was piloted between August 2016 March 2017. Qualitative...
Successive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have caused disease in long-term care facility (LTCF) residents. Primary vaccination provides strong short-term protection, but data are limited on duration of protection following booster vaccines, particularly against the Omicron variant. We investigated effectiveness infections, hospitalizations, and deaths among LTCF residents staff England. included LTCFs within VIVALDI study (ISRCTN 14447421) who underwent...